Protocol for MInimizing the Risk of Metachronous Adenomas of the CoLorectum with Green Tea Extract (MIRACLE): A randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Stingl, Julia C ^a   Ettrich, Thomas ^b   Muche, Rainer ^a   Wiedom, Martina ^a   Brockmöller, Jürgen ^c   Seeringer, Angela ^a   Seufferlein, Thomas ^b  

^a UNIVERSITY OF ULM   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; PLACEBO; CATECHIN; DRUG DERIVATIVE; PLANT EXTRACT;

ADULT; AGED; ARTICLE; COLONOSCOPY; COLORECTAL ADENOMA; DIET SUPPLEMENTATION; DRUG EFFICACY; FEMALE; GERMANY; HISTOPATHOLOGY; HUMAN; MALE; MULTICENTER STUDY (TOPIC); PLANT LEAF; POLYPECTOMY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; STUDY DESIGN; TREATMENT OUTCOME; ADENOMA; CHEMISTRY; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; TEA; TUMOR RECURRENCE;

ADENOMA; AGED; AGED, 80 AND OVER; CAMELLIA SINENSIS; CATECHIN; COLONIC NEOPLASMS; COLONOSCOPY; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PLACEBOS; PLANT EXTRACTS;

EID: 80051801925     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-360     Document Type: Article

References (40)

1. Cancer WCRFAIf, Research Food, Nutrition, and Physical Activity, and the Prevention of Cancer: A Global Perspective. 2007, Washington, DC: AICR, Cancer WCRFAIf, Research.
2. Widlansky ME, Hamburg NM, Anter E, Holbrook M, Kahn DF, Elliott JG, Keaney JF, Vita JA. Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. J Am Coll Nutr 2007, 26(2):95-102.
3. Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, Tsubono Y, Tsuji I. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. Jama 2006, 296(10):1255-1265. 10.1001/jama.296.10.1255, 16968850.
4. Cabrera C, Artacho R, Gimenez R. Beneficial effects of green tea--a review. J Am Coll Nutr 2006, 25(2):79-99.
5. Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP, Gescher AJ. Dietary polyphenolic phytochemicals--promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer 2007, 120(3):451-458. 10.1002/ijc.22419, 17131309.
6. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 2009, 27(23):3808-3814. 10.1200/JCO.2008.21.1284, 2727287, 19470922.
7. Fukino Y, Ikeda A, Maruyama K, Aoki N, Okubo T, Iso H. Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities. Eur J Clin Nutr 2008, 62(8):953-960. 10.1038/sj.ejcn.1602806, 17554248.
8. McKay DL, Blumberg JB. The role of tea in human health: an update. J Am Coll Nutr 2002, 21(1):1-13.
9. Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, Suganuma M, Fujiki H, Moriwaki H. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev 2008, 17(11):3020-3025. 10.1158/1055-9965.EPI-08-0528, 18990744.
10. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993, 9(4):138-141. 10.1016/0168-9525(93)90209-Z, 8516849.
11. Ladenheim J, Garcia G, Titzer D, Herzenberg H, Lavori P, Edson R, Omary MB. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995, 108(4):1083-1087. 10.1016/0016-5085(95)90206-6, 7698575.
12. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003, 348(10):883-890. 10.1056/NEJMoa021633, 12621132.
13. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003, 348(10):891-899. 10.1056/NEJMoa021735, 12621133.
14. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003, 125(2):328-336. 10.1016/S0016-5085(03)00887-4, 12891533.
15. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 131(6):1674-1682. 10.1053/j.gastro.2006.08.079, 17087947.
16. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355(9):873-884. 10.1056/NEJMoa061355, 16943400.
17. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355(9):885-895. 10.1056/NEJMoa061652, 16943401.
18. Half E, Arber N. Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother 2009, 10(2):211-219. 10.1517/14656560802560153, 19236194.
19. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007, 146(5):365-375.
20. Ju J, Hong J, Zhou JN, Pan Z, Bose M, Liao J, Yang GY, Liu YY, Hou Z, Lin Y, Ma J, Shih WJ, Carothers AM, Yang CS. Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res 2005, 65(22):10623-10631. 10.1158/0008-5472.CAN-05-1949, 16288056.
21. Issa AY, Volate SR, Muga SJ, Nitcheva D, Smith T, Wargovich MJ. Green tea selectively targets initial stages of intestinal carcinogenesis in the AOM-ApcMin mouse model. Carcinogenesis 2007, 28(9):1978-1984. 10.1093/carcin/bgm161, 17638923.
22. Peng G, Dixon DA, Muga SJ, Smith TJ, Wargovich MJ. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol Carcinog 2006, 45(5):309-319. 10.1002/mc.20166, 16508969.
23. Shimizu M, Deguchi A, Joe AK, McKoy JF, Moriwaki H, Weinstein IB. EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. J Exp Ther Oncol 2005, 5(1):69-78.
24. Sun CL, Yuan JM, Koh WP, Yu MC. Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies. Carcinogenesis 2006, 27(7):1310-1315. 10.1093/carcin/bgi276, 16311246.
25. Nakachi K, Matsuyama S, Miyake S, Suganuma M, Imai K. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors 2000, 13(1-4):49-54. 10.1002/biof.5520130109, 11237198.
26. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6):649-655. 10.1097/00000421-198212000-00014, 7165009.
27. Rohlmann F, Muche R, Goldschmidt L. Randomisierung in klinischen Studien: Praktische Umsetzung mit dem Randomisationsprogramm ROM. 2004, Ulm: Universitätsverlag Ulm.
28. Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R, Mahady GB, Marles RJ, Pellicore LS, Giancaspro GI, Low Dog T. Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf 2008, 31(6):469-484. 10.2165/00002018-200831060-00003, 18484782.
29. Ullmann U, Haller J, Decourt JP, Girault N, Girault J, Richard-Caudron AS, Pineau B, Weber P. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res 2003, 31(2):88-101.
30. Chow HH, Cai Y, Alberts DS, Hakim I, Dorr R, Shahi F, Crowell JA, Yang CS, Hara Y. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 2001, 10(1):53-58.
31. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, Alberts DS. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003, 9(9):3312-3319.
32. Netsch MI, Gutmann H, Schmidlin CB, Aydogan C, Drewe J. Induction of CYP1A by green tea extract in human intestinal cell lines. Planta Med 2006, 72(6):514-520. 10.1055/s-2006-931537, 16773535.
33. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007, 369(9573):1603-1613. 10.1016/S0140-6736(07)60747-8, 17499602.
34. Tanner MA, . WWH The Calculation of Posterior Distributions by Data Augmentation. Journal of the American Statistical Association 1987, 18:528-540. WWH.
35. Bland M. An introduction to medical statistics. 2000, New York: Oxford University Press.
36. Hosmer D, Lemeshow S. Applied logistic regression. 2000, New York.: Wiley.
37. Kleinbaum DG. Survival Analysis - A self learning text. 1996, New York.: Springer.
38. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006, 66(2):1234-1240. 10.1158/0008-5472.CAN-05-1145, 16424063.
39. Kajimoto O, Kajimoto Y, Yabune M, Nakamura T, Kotani K, Suzuki Y, Nozawa A, Nagata K, Unno T, Sagesaka Y, Kakuda T, Yoshikawa T. Tea Catechins with a Galloyl Moiety Reduce Body Weight and Fat. Journal of Health Science 2005, 51(2):161-171.
40. McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila) 2009, 2(7):673-682.